Finnish researchers found that hemoglobin levels that are within the normal range but at the lower end may be beneficial for ...
Treatment with the investigational base-editing gene therapy ristoglogene autogetemcel (risto-cel) showed promise in patients with sickle cell disease, according to an interim ana ...
New results from a clinical trial show promising outcomes for a gene-edited treatment for severe sickle cell disease, a ...
If you’ve ever had a blood test for sugar, you’ve probably seen this term on your report—HbA1c. And for many people, it’s confusing. It doesn’t feel as straightforward as a fasting or post-meal sugar ...
The Chosun Ilbo on MSN
Zone 2 training: Walking to combat diabetes and hypertension
He was diagnosed with diabetes one year ago. His fasting blood sugar level was 138 mg/dL, and his glycated hemoglobin was 6.8 ...
New results from a clinical trial show promising outcomes for a gene-edited treatment for severe sickle cell disease , a genetic blood disorder with ...
MedPage Today on MSN
FDA Signals Regulatory Flexibility With Accelerated Approval of Rare Disease Drug
Tividenofusp alfa is the first approved treatment for neurologic complications of Hunter s ...
"Heat adaptation means that the next heat wave or hot spell is less taxing on you," Gifford explains. "That becomes relevant ...
A therapy for Hunter syndrome shows a significant reduction in disease-linked molecules in cerebrospinal fluid. Findings ...
February was heart month, and this is the fourth column in a series about the primary risk factors for heart attacks. Sleep ...
The U.S. Food and Drug Administration has approved Avlayah (tividenofusp alfa-eknm) to treat certain individuals with Hunter syndrome (Mucopolysaccharidosis type II or MPS II). “Today is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results